EGFR and neoplasm: Comprehensive genomic analyses of tumors from both PDX models and patients whose tumor responded to anti-EGFR antibody blockade detected mutations in ERBB2, EGFR, FGFR1, PDGFRA, and MAP2K1 as potential mechanisms of primary resistance to this therapy [15].